Merck & Co. Inc. (MRK)

69.06
0.21 0.30
NYSE : Health Technology
Prev Close 68.85
Open 68.78
Day Low/High 68.70 / 69.23
52 Wk Low/High 52.83 / 69.00
Volume 7.83M
Avg Volume 8.94M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 179.17B
EPS 0.90
P/E Ratio 134.74
Div & Yield 1.92 (2.87%)

Latest News

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

- Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Time to brace for a summer pullback?

Merck Becomes #17 Most Shorted Dow Stock, Replacing Travelers Companies

Merck Becomes #17 Most Shorted Dow Stock, Replacing Travelers Companies

The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

4 of My Recent Income Picks Had Good Earnings

From Stag Industrial to Merck, the numbers looked good.

This Market Isn't Weak, It's Just Tired

The market needs a pullback.

Merck's Head Of Human Resources Mirian M. Graddick-Weir To Retire; Steven C. Mizell Will Assume Role On Oct. 1

Merck's Head Of Human Resources Mirian M. Graddick-Weir To Retire; Steven C. Mizell Will Assume Role On Oct. 1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the retirement effective November 30, 2018 of its chief human resources officer Mirian M.

Selumetinib Granted Orphan Designation In Europe For Neurofibromatosis Type 1

Selumetinib Granted Orphan Designation In Europe For Neurofibromatosis Type 1

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S.

Healthcare Bulls Are Feeling Great After Earnings

Healthcare Bulls Are Feeling Great After Earnings

Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.

European Medicines Agency Adopts Positive Opinion For KEYTRUDA® (pembrolizumab) Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer

European Medicines Agency Adopts Positive Opinion For KEYTRUDA® (pembrolizumab) Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA ®,...

Stocks Trim Losses at Close of Trading

Stocks Trim Losses at Close of Trading

Stocks ended the day off their lows but still in the red Friday as tech share weakness overcame strong GDP data.

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Shares fell on Friday morning despite positive results for the second quarter.

Global Stocks Grind Higher as Trade Tension Ease: U.S. GDP in Focus

Global Stocks Grind Higher as Trade Tension Ease: U.S. GDP in Focus

With global trade tensions easing and U.S. corporate earnings continuing to impress, stocks are set to close out the week on solid footing, with gains possibly extended by a better-than-expected reading for U.S. economic growth over the second quarter.

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2018.

KEYTRUDA® (pembrolizumab) Is The First Anti-PD-1 Therapy Approved In China For Advanced Melanoma

KEYTRUDA® (pembrolizumab) Is The First Anti-PD-1 Therapy Approved In China For Advanced Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA ®, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or...

REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head...

KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head...

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

Merck Announces Fourth-Quarter 2018 Dividend

Merck Announces Fourth-Quarter 2018 Dividend

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-FORWARD Study Of Its Investigational HIV Therapy Doravirine

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-FORWARD Study Of Its Investigational HIV Therapy Doravirine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical trial evaluating the efficacy and safety of doravirine (DOR), the company's investigational non-nucleoside...

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.

Merck Reinforces Commitment To Responsible Pricing

Merck Reinforces Commitment To Responsible Pricing

Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing.

Four Great, Conservative Income Stocks

From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Advanced Hepatocellular Carcinoma

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Advanced Hepatocellular Carcinoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

General Electric's Stock Is Attractive for the First Time in 2 Years: Jim Cramer

General Electric's Stock Is Attractive for the First Time in 2 Years: Jim Cramer

Jim Cramer says earnings could break the tie between the bulls and the bears -- unless China blinks. Here's the game plan for next week.

The New #22 Most Shorted Dow Component: Merck

The New #22 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 06/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: B+ (Buy)